We chose CpG-free human factor IX of the Padua variant to develop gene therapy for hemophilia B. The Padua variant of factor IX, having an amino acid change at R338L, demonstrated a gain of functions in clotting activity over 8-fold compared to the wild type [13]. Here, F9 is linked to hemophilia B.